Date Title Description PDF
27 Nov 2020 On business and financial situation The Company publishes the results of the PRISMA-3 study of the efficacy and safety of Doria® in schizophrenic patients in the journal npj Schizophrenia Download
09 Jul 2020 On business and financial situation ROVI informs on the Collaboration with Moderna for Outside the United States Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate Download

Pages

Date Title Description PDF
28 Jul 2023 On business and financial situation ROVI informs on the evaluation process to obtain marketing authorisation for Risvan® Download
05 Jul 2023 Liquidity and counterparty agreements Liquidity contract: transactions conducted in the second quarter of 2023 Download
26 Jun 2023 Other relevant information The Company informs about the dividends payment Download
14 Jun 2023 Announcement of general shareholders’ meeting ROVI releases the information related to its General Shareholders Meeting. Download
31 May 2023 Other relevant information ROVI informs about the news items that have appeared in several media today regarding ROVI’s receipt of government grants Download

Pages

Date Title Description PDF
26 Feb 2019 Información sobre resultados ROVI releases the presentation related to the full year 2018 results Download
26 Feb 2019 Información sobre resultados ROVI releases the press release related to the full year 2018 results Download
15 Feb 2019 Others on business performance and financial information ROVI acquires rights to Dexchlorpheniramine Maleate in the Spanish and French markets Download
09 Jan 2019 Others on business performance and financial information ROVI informs about the adquisition of Falithrom® for the German market Download
08 Jan 2019 Liquidity contracts and specialists Liquidity contract: transactions conducted in the fourth quarter of 2018 Download

Pages